Manoj R Kumbhare,Rutuja Porje,Arshad Shaikh
Manoj R Kumbhare
Iridium therapy is changing how cancer is treated in the future. Because of their remarkable photophysics, redox sensitivity, and structural adaptability, Ir (III) complexes offer a powerful and multipurpose solution for precision oncology....
Next-Generation Targeted Therapy: The Evolving Role of Taletrectinib in Fusion-Positive Malignancies [0.03%]
下一代靶向治疗：Taletrectinib在阳性融合肿瘤中的作用日益重要
Samiksha Mankar,Manoj Kumbhare,Siddhi Chandak et al.
Samiksha Mankar et al.
The discovery of ROS1 and NTRK gene fusions has transformed treatment strategies for a specific group of cancers, particularly non-small cell lung cancer (NSCLC). First-generation tyrosine kinase inhibitors (TKIs) such as crizotinib display...
Cardiotoxicity in Contemporary Treatments: New Issues, Mechanisms, and Preventive Techniques [0.03%]
当代治疗中的心脏毒性：新问题、机制和预防技术
Nirmala V Shinde,Swarali A Pawar,Sachin K Bhosale et al.
Nirmala V Shinde et al.
Introduction: Worldwide, heart failure remains one of the leading causes of death and morbidity. Drug-induced cardiotoxicity is a significant adverse effect on cardiovascular health and may arise from various pathogenic m...
AI-Driven Early Detection of Diabetic Glaucoma and Emerging Horizons in Bionic Eye Technology [0.03%]
人工智能驱动的糖尿病性青光眼早期检测及仿生眼技术的新视野
Gaurav Tiwari,Ankita Wal,Raghuraj Singh Suryavanshi et al.
Gaurav Tiwari et al.
Background: Diabetic glaucoma is a serious eye disorder that can lead to permanent vision loss and is increasingly seen in individuals with long-term diabetes. With its rising global incidence, there is a critical need fo...
Aprocitentan in Resistant Hypertension: Mechanistic Insights, Clinical Evidence, and Future Directions [0.03%]
用于难治性高血压的Aprocitentan：机制见解、临床证据和未来发展方向
Manoj Kumbhare,Bhagwan Rajendra Ide,Arshad Shaikh et al.
Manoj Kumbhare et al.
Resistant Hypertension is a significant clinical problem. It is found in the most of individuals who, even with the greatest multi-drug therapy, are not able to manage their blood pressure. A new dual endothelin receptor antagonist (ERA) ca...
Targeting PLK1 in myelodysplastic syndromes: The Role of Rigosertib in Precision Medicine [0.03%]
PLK1在骨髓增生异常综合征治疗中的作用：Rigosertib在精准医学中的地位
Vedant Patil,Sujata Lambe,Anand Lokhande et al.
Vedant Patil et al.
Rigosertib (ON 01910.Na) is a novel multi-kinase inhibitor initially developed as a non-ATP competitive agent, targeting dysregulated signalling pathways in cancer cells, notably RAS/RAF/MEK/ERK and PI3K/AKT, alongside Polo-like kinase 1 (P...
3D Printing in Pharmaceuticals: A Mini Review of Materials, Techniques and Challenges [0.03%]
制药业中的三维打印：材料、技术及挑战的简评
Barnali Mandal,Sanjesh Rathi,Shubham Singh
Barnali Mandal
The production procedures for pharmaceuticals and medical equipment have advanced significantly in recent years, especially considering the current pandemic and supply chain disruptions. Actually, 3D printers are a cutting-edge technology t...
Single Cell Transcriptomics of Traditional Chinese Medicine Bioactives: Mapping Immune, Neural and Hepatic Responses [0.03%]
单细胞转录组学研究中药活性成分：探索免疫、神经和肝部的反应路径
Shubham Singh,Sakshi Singh,Sayli Saw et al.
Shubham Singh et al.
Traditional Chinese medicine (TCM) bioactives display wide pharmacological effects, yet bulk transcriptomic studies mask their cell-specific actions. This study applied single-cell RNA sequencing to delineate immune, neural and hepatic resp...
Targeting ROS1 in NSCLC: Clinical Advances and Future Directions of Taletrectinib [0.03%]
针对ROS1阳性NSCLC的塔拉西替尼(TALETRECTINIB)临床研究进展与未来展望
Manoj Kumbhare,Nishant Dattatray Pagere,Bhagwan Ide et al.
Manoj Kumbhare et al.
This review looks at the pharmacokinetics, safety, and effectiveness of taletrectinib, a novel inhibitor that targets both ROS1 and NTRK, in patients with solid tumors and ROS1-positive non-small cell lung cancer (NSCLC). Objective response...
The Role of Non-Helicobacter Pylori Bacteria in the Pathogenesis of Gastric Diseases [0.03%]
非幽门螺旋杆菌胃病致病菌的作用
Ruchi Tiwari,Gaurav Tiwari,Anshu Gupta et al.
Ruchi Tiwari et al.
In the context of dysbiosis, chronic inflammation, and carcinogenesis, non-Helicobacter pylori bacteria are becoming more widely acknowledged as significant contributors to stomach diseases. The stomach contains a variety of bacterial commu...